ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Mallinckrodt to buy Sucampo for $1.2 billion

by Rick Mullin
January 8, 2018 | APPEARED IN VOLUME 96, ISSUE 2

Mallinckrodt has agreed to acquire Sucampo Pharmaceuticals, a Rockville, Md.-based drugmaker, for $1.2 billion. With the deal, Mallinckrodt will pick up two approved drugs: Amitiza, a treatment for various bowel diseases with 2016 sales of $456 million, and Rescula, a treatment for ocular hypertension and glaucoma with annual sales of about $9 million. Mallinckrodt CEO Mark Trudeau says the deal also bolsters the company’s rare disease drug pipeline with VTS-270, in development for Niemann-Pick disease type C1, and CPP-1X/sulindac, in development for familial adenomatous polyposis.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment